UOC
VTVT icon

UBS O'Connor’s vTv Therapeutics VTVT Stock Holding History

UBS O'Connor’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,835
Closed -$500K – 537
2015
Q4 		$500K Sell
1,835
-165
-8% -$46.3K ﹤0.01% 385
2015
Q3 		$522K Buy
+2,000
New +$697K ﹤0.01% 458

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

UBS O'Connor's VTVT Position: Q1 2016 in Review

UBS O'Connor sold out of vTv Therapeutics (VTVT) in Q1 2016, closing a stake of 1,835 shares — an estimated $500K sold.

UBS O'Connor first reported a position in VTVT in Q3 2015 and held it in 2 quarters. The position peaked at $522K in Q3 2015. 41 funds tracked by Wall St. Rank hold VTVT as of Q1 2016.

  • UBS O'Connor reported no remaining vTv Therapeutics position as of Q1 2016 after selling out during the quarter.
  • UBS O'Connor sold 1,835 vTv Therapeutics shares in Q1 2016, an estimated $500K.
  • UBS O'Connor first reported a position in vTv Therapeutics in Q3 2015 and held it in 2 quarters.
  • UBS O'Connor's vTv Therapeutics position peaked at $522K in Q3 2015.
  • 41 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2016.

Based on UBS O'Connor's 13F filing for Q1 2016, filed 13 May 2016.